fibrosis

AI and high-throughput functional screening helped researchers design antibodies that selectively activate CB2, reducing inflammation and scar tissue in human liver tissue.

A disease once synonymous with a shortened lifespan is now a model for how drug discovery can directly alter the natural history of genetic disorders.

A strain of E. coli linked to Crohn’s disease produces a compound that triggers intestinal scarring, revealing a potential treatment path.

Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.

A liver enzyme affects fibrosis progression by altering metabolism of the sugar trehalose in the gut.

Injecting lung stem cells into the bloodstream of mice with idiopathic pulmonary fibrosis improved their lung function, setting the stage for human trials.